MICE MODEL MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

The Global Mice Model Market is estimated to be valued at USD 1.86 Bn in 2025 and is expected to reach USD 3.60 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.9% from 2025 to 2032. The global mice model market represents a critical segment within the broader biomedical research ecosystem, serving as an indispensable tool for scientific discovery and pharmaceutical development. Laboratory mice, particularly genetically modified strains, have become the gold standard for preclinical research due to their genetic similarity to humans, well-characterized biological systems, and established research protocols. This market encompasses various mouse models including inbred strains, outbred stocks, Genetically Engineered Models (GEMs), and immunodeficient mice, each designed to replicate specific human diseases and conditions.

The increasing prevalence of chronic diseases, cancer, neurological disorders, and metabolic conditions has intensified the demand for sophisticated animal models that can accurately mimic human pathophysiology. Academic institutions, pharmaceutical companies, biotechnology firms, and contract research organizations heavily rely on these models for drug discovery, toxicology studies, efficacy testing, and personalized medicine research. The market's growth is further propelled by technological advancements in genetic engineering techniques such as CRISPR-Cas9, which enable the development of more precise and disease-specific mouse models, thereby enhancing research outcomes and accelerating the translation of laboratory findings into clinical applications.

Market Dynamics

The global mice model market growth is driven by several compelling factors that collectively fuel its robust expansion across the pharmaceutical and biotechnology sectors. The primary driver stems from the exponential growth in drug discovery and development activities, where pharmaceutical companies increasingly rely on sophisticated mouse models to evaluate therapeutic efficacy and safety profiles before advancing to human trials. The rising prevalence of chronic diseases, including cancer, diabetes, cardiovascular disorders, and neurological conditions, necessitates the development of disease-specific mouse models that can accurately replicate human pathophysiology, thereby driving market demand.

Additionally, technological advancements in genetic engineering, particularly CRISPR-Cas9 and other gene-editing technologies, have revolutionized the creation of genetically modified mouse models, enabling researchers to develop more precise and targeted experimental systems. However, the market faces significant restraints that challenge its growth trajectory. Stringent regulatory frameworks governing animal research, including ethical considerations and compliance requirements, create barriers for market expansion and increase operational costs for research institutions. The growing emphasis on alternative testing methods, such as in-vitro models, organ-on-chip technologies, and computational modeling, poses a potential threat to traditional animal-based research paradigms. Furthermore, the high costs associated with breeding, maintaining, and housing specialized mouse strains, coupled with the need for specialized facilities and trained personnel, limit accessibility for smaller research organizations.

Despite these challenges, substantial opportunities emerge from the increasing adoption of personalized medicine approaches, which require patient-specific mouse models for tailored therapeutic development. The expansion of contract research organizations offering specialized mouse model services presents lucrative opportunities for market growth, particularly in emerging markets where research infrastructure is rapidly developing.

Key Features of the Study

• This report provides in-depth analysis of the global mice model market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global mice model market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Charles River Laboratories, The Jackson Laboratory, Inotiv, genOway, Taconic Biosciences, Janvier Labs, Crown Bioscience, Cyagen Biosciences, GemPharmatech, Shanghai Model Organisms Center (SMOC), Biocytogen, Ozgene Pty Ltd, Trans Genic Inc., Harbour BioMed, and JSR Life Sciences
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global mice model market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global mice model market

Market Segmentation

• Model Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Genetically Engineered Mice (GEM)
    • Knockout Mice
    • Knock-in Mice
    • Conditional Mutant Mice
  • Inbred Mice
  • Outbred Mice
  • Hybrid/Congenic Mice
  • Spontaneous Mutant Mice
• Service Insights (Revenue, USD Bn, 2020 - 2032)
  • Breeding Services
  • Cryopreservation, Rederivation, and Resequencing Services
  • Genetic Testing and Characterization Services
  • Model In-vivo and In-vitro Testing Services
  • Custom Model Development Services
• Technology Insights (Revenue, USD Bn, 2020 - 2032)
  • CRISPR/Cas9
  • Embryonic Stem Cell (ESC) Technology
  • Nuclear Transfer Technology
  • Microinjection Technology
  • Others (e.g., TALENs, ZFNs)
• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Oncology Research
  • Immunology and Inflammation Studies
  • Diabetes Research
  • Cardiovascular Research
  • Neurological Disease Research
  • Rare Disease Research
  • Toxicology and Safety Assessment
  • Others (e.g., Metabolic Disorders, Infectious Diseases)
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutions
  • Contract Research Organizations (CROs)
  • Government and Nonprofit Organizations
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Charles River Laboratories
  • The Jackson Laboratory
  • Inotiv
  • genOway
  • Taconic Biosciences, Inc.
  • Janvier Labs
  • Crown Bioscience
  • Cyagen
  • GemPharmatech
  • Shanghai Model Organisms Center, Inc.
  • Biocytogen
  • Ozgene Pty Ltd
  • Trans Genic Inc.
  • Harbour BioMed
  • JSR Life Sciences, LLC